Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clive Page Insider Profile
4 Followers
Clive Page, Director at Verona Pharma, holds 6.03M shares in Verona Pharma (Ticker: GB:VRP), holds 6.03M shares in Verona Pharma (Ticker: VRNA). Most recently, Clive Page ― shares of Verona Pharma on ― for an estimated value of ―.
Clive Page Verona Pharma (VRP)Director
Verona Pharma (VRP)
Director
Not Ranked
Clive Page has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director
Roles that Clive Page holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Clive Page
Clive Page's Trading History
Verona Pharma
―
―
―
£3.32M
Verona Pharma
―
Director
―
$232.82M
List of latest transactions for each holding click on a transaction to see Clive Page's performance on stock
You May Also Like
Clive Page insider profile FAQ
What is the percentage of profitable transactions made by Clive Page?
The percentage of profitable transactions made by Clive Page is ―.
What is the average return per transaction made by Clive Page?
The average return per transaction made by Clive Page is ―.
What stocks does Clive Page hold?
Clive Page holds: GB:VRP, VRNA stocks.
What was Clive Page’s latest transaction?
Clive Page latest transaction was an Uninformative Buy of ―.
What was Clive Page's most profitable transaction?
Clive Page’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Clive Page's role in Verona Pharma?
Clive Page's role in Verona Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.